Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
PHASE1Not yet recruitingINTERVENTIONAL
Enrollment
18
Participants
Timeline
Start Date
December 1, 2025
Primary Completion Date
December 1, 2028
Study Completion Date
December 1, 2028
Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Interventions
DRUG
RPT1G
RPT1G is a selective hyperbolic NAMPT inhibitor. RPT1G is administered orally.
All Listed Sponsors
lead
Remedy Plan, Inc.
INDUSTRY
NCT07107126 - Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter